HULC: an oncogenic long non-coding RNA in human cancer.
HULC: an oncogenic long non-coding RNA in human cancer.
复制标题
HULC：人类癌症中的致癌长无编码RNA。
DOI：
10.1111/jcmm.12956
复制
发表时间：
2017-02
影响因子：
5.3
通讯作者：
Wu WK
中科院分区：
文献类型：
--
作者：
Yu X;Zheng H;Chan MT;Wu WK
在肝癌中高度上调（HULC）最初被确定为肝细胞癌中过度表达最多的长链非编码RNA。自发现以来，HULC的异常上调已在其他类型的癌症中得到证实，包括胃癌、胰腺癌、骨肉瘤和结直肠癌的肝转移。最近的发现也揭示了HULC解除管制的上游分子机制。作为致癌基因，HULC通过下调EEF1E1、促进异常脂质代谢、上调鞘氨醇激酶1等多种途径促进肿瘤发生。在临床实践中，已经发现HULC基因的遗传变异可改变肝癌和食管癌的风险，而HULC高表达或低表达的癌症患者表现出不同的临床结果。这些发现强调了HULC在人类癌症中的致病作用和临床应用。需要进一步努力促进以HULC为导向的治疗方法的发展。
Highly up‐regulated in liver cancer (HULC) was originally identified as the most overexpressed long non‐coding RNA in hepatocellular carcinoma. Since its discovery, the aberrant up‐regulation of HULC has been demonstrated in other cancer types, including gastric cancer, pancreatic cancer, osteosarcoma and hepatic metastasis of colorectal cancer. Recent discoveries have also shed new light on the upstream molecular mechanisms underlying HULC deregulation. As an oncogene, HULC promotes tumorigenesis by regulating multiple pathways, such as down‐regulation of EEF1E1, promotion of abnormal lipid metabolism, and up‐regulation of sphingosine kinase 1. Pertinent to clinical practice, a genetic variant in the HULC gene has been found to alter the risk for hepatocellular carcinoma and oesophageal cancer, whereas cancer patients with high or low expression of HULC exhibit different clinical outcome. These findings highlighted the pathogenic role and clinical utility of HULC in human cancers. Further efforts are warranted to promote the development of HULC‐directed therapeutics.